Artiva Biotherapeutics, Inc. (ARTV) — Stock Score Summary

Artiva Biotherapeutics, Inc. (ARTV) has a MoatMap StockRank of 40/100 based on Quality (32/100), Value (37/100), and Momentum (58/100) factor scores. The current signal is HOLD. As an early-stage, unprofitable clinical biotech company, Artiva is a consumer rather than a provider of manufacturing capacity, making it highly vulnerable to rising CDMO pricing power.

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing off-the-shelf allogeneic natural killer (NK) cell therapies for various cancers. The company's proprietary platform aims to provide readily available and scalable cell therapy options, overcoming the manufacturing complexities and patient-specific limitations of autologous treatments. Its competitive edge is rooted in its innovative approach to leveraging NK cell biology to create potentially transformative cancer immunotherapies.

Key Financial Metrics

Price$7.27
Market Cap$370M
P/E (Forward)-2.73
Price/Book2.16
Return on Equity-67.9%
Return on Invested Capital-76.2%
Debt/Equity11.68
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-49M

Artiva Biotherapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Artiva Biotherapeutics, Inc.’s (ARTV) StockRank?
MoatMap’s StockRank for Artiva Biotherapeutics, Inc. (ARTV) is 40/100, with a Hold signal. It is a composite of Quality (32), Value (37), and Momentum (58) factor ranks across MoatMap’s 19,000+ stock universe.
Does Artiva Biotherapeutics, Inc. have an economic moat?
Artiva Biotherapeutics, Inc. (ARTV) has a Quality factor score of 32/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Artiva Biotherapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Artiva Biotherapeutics, Inc. (ARTV) is Hold, based on a StockRank of 40/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Artiva Biotherapeutics, Inc. in?
Artiva Biotherapeutics, Inc. (ARTV) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksARTV deep dive reportAI ChampionsHow we score stocksSense-check another stock